
|Videos|February 7, 2022
Why PSMA imaging is unique from other prostate cancer imaging technologies
Author(s)Urology Times staff
We've never had an imaging agent like this before,” says Leonard S. Marks, MD.
Advertisement
In this video, Leonard S. Marks, MD, gives an overview of the Journal of Urology review on prostate-specific antigen membrane imaging for prostate cancer. He details how this technology will affect the detection and treatment of patients with this disease and is hopeful of its real-world application in the future. Marks is a deKernion Endowed Chair in Urology at the David Geffen School of Medicine at the University of California, Los Angeles.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












